Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Clinical efficacy and inflammatory factors in knee osteoarthritis with glucosamine hydrochloride plus meloxicam

Lin Zhang, Bing Zhang, Jin Kang, Bo Li

Department of Orthopeadic Surgery, The Second Affiliated Hospital of Xi’an Medical College, Xi’an, China;

For correspondence:- Bo Li Email: libo668888@126.com Tel:+8613572276880

Accepted: 11 February 2022 Published: 31 March 2022

Citation: Zhang L, Zhang B, Kang J, Li B. Clinical efficacy and inflammatory factors in knee osteoarthritis with glucosamine hydrochloride plus meloxicam. Trop J Pharm Res 2022; 21(3):673-678 doi: 10.4314/tjpr.v21i3.30

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the efficacy and change in serum levels of inflammatory factors in knee osteoarthritis (KOA) treated with glucosamine hydrochloride plus meloxicam.

Methods: In total, 114 patients with KOA who received glucosamine hydrochloride plus meloxicam treatment were included in the study and equally distributed to a control group and a study group. The control group received glucosamine hydrochloride, and the study group received a similar treatment but, received in additional, meloxicam. Clinical efficacy, numerical rating scale (NRS) score, quality of life (QoL) score, index of severity for osteoarthritis (ISOA) score, and related inflammatory factors were assessed and compared.

Results: The study group outperformed the control group in terms of clinical efficacy. Significantly lower NRS scores were obtained in the study group at T2, T3, and T4 than those of the control group (p < 0.001). Before treatment, the two groups presented similar ISOA score, QoL score, and interleukin (IL)-6 and tumor necrosis factor- α (TNF-α) levels. After treatment, ISOA score, and IL-6 and TNF-α levels declined in all patients, with lower results obtained in the study group. All patients obtained significantly higher Qol score after treatment, with higher outcomes observed in the study group.

Conclusion: The combination of glucosamine hydrochloride and meloxicam effectively improves the joint function of patients with KOA and relieves symptoms such as joint swelling and pain. Hus, t treatment strategy has great promise

Keywords: Glucosamine, Meloxicam, Knee osteoarthritis, Serum inflammatory Factors